Results 241 to 250 of about 4,013,382 (355)
Identification of fibrinogen as a plasma protein binding partner for lecanemab biosimilar IgG. [PDF]
Bellier JP+15 more
europepmc +1 more source
In Vitro Analyses of the Binding of 131I-Iodide to Milk Protein
G. D. Potter, David R. McIntyre
openalex +1 more source
This review highlights how foundation models enhance predictive healthcare by integrating advanced digital twin modeling with multiomics and biomedical data. This approach supports disease management, risk assessment, and personalized medicine, with the goal of optimizing health outcomes through adaptive, interpretable digital simulations, accessible ...
Sakhaa Alsaedi+2 more
wiley +1 more source
Generating and validating renewable affimer protein binding reagents targeting SH2 domains. [PDF]
Heseltine SJ+11 more
europepmc +1 more source
The tumor microenvironment is a dynamic, multifaceted complex system of interdependent cellular, biochemical, and biophysical components. Three‐dimensional in vitro models of the tumor microenvironment enable a better understanding of these interactions and their impact on cancer progression and therapeutic resistance.
Salma T. Rafik+3 more
wiley +1 more source
Non-linear plasma protein binding of cannabidiol. [PDF]
Babayeva M, Srdanovic I.
europepmc +1 more source
Liver‐specific knockout of N6‐methyladenosine (m6A) methyltransferase METTL3 significantly accelerated hepatic tumor initiation under various oncogenic challenges, contrary to the previously reported oncogenic role of METTL3 in liver cancer cell lines or xenograft models. Mechanistically, METTL3 deficiency reduced m6A deposition on Manf transcripts and
Bo Cui+15 more
wiley +1 more source
Structures of complete HIV-1 TAR RNA portray a dynamic platform poised for protein binding and structural remodeling. [PDF]
Bou-Nader C+4 more
europepmc +1 more source
Purification and Properties of a Leucine-binding Protein from Escherichia coli
W.R. Penrose+3 more
openalex +1 more source
The A3 adenosine receptors (A3ARs) are overexpressed in prostate cancer. AR 292 and AR 357, as A3AR antagonists, are capable of blocking proliferation, modulating the expression of drug transporter genes involved in chemoresistance, ferroptosis, and the hypoxia response, and inducing cell death.
Maria Beatrice Morelli+15 more
wiley +1 more source